Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models

被引:10
|
作者
Yang, Mei [1 ]
Guan, Tian [2 ]
Chen, Chun-Fa [3 ]
He, Li-Fang [3 ]
Wu, Hao-Ming [3 ]
Zhang, Ren-Dong [3 ]
Li, Yun [2 ]
Lin, Yan-Chun [2 ]
Zeng, Haoyu [2 ,6 ]
Wu, Jun-Dong [3 ,4 ,5 ]
机构
[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Canc Ctr, Dept Breast Canc, Shantou, Guangdong, Peoples R China
[2] Guangdong Procapzoom Biosci Inc, Guangzhou, Guangdong, Peoples R China
[3] Shantou Univ, Canc Hosp, Med Coll, Breast Ctr, Shantou, Guangdong, Peoples R China
[4] Guangdong Prov Key Lab Breast Canc Diag & Treatmen, Shantou, Guangdong, Peoples R China
[5] Guangdong Prov Key Lab Breast Canc Diag & Treatmen, Shantou 515041, Guangdong, Peoples R China
[6] Guangdong Procapzoom Biosci, Dept Stem Cell Res, 11 Guangpuzhong Rd, Guangzhou 510700, Guangdong, Peoples R China
关键词
CAR-NK; iPSCs; TNBC; pre-clinical; MSLN;
D O I
10.1097/CJI.0000000000000483
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The emergence of immunotherapy has introduced a promising, novel approach to cancer treatment. While multiple chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable clinical efficacy against leukemia, their effect on solid tumors has been limited. One potential option for treating solid tumors is the engineering of natural killer (NK) cells with CARs. Mesothelin (MSLN), a tumor differentiation antigen, is expressed on triple-negative breast cancer (TNBC) cells, making it a potential target for CAR-NK therapy in the treatment of TNBC. We first constructed induced pluripotent stem cells with stable anti-MSLN-CAR expression and subsequently differentiated these cells into mesothelin-targeted CAR-NK (MSLN-NK) cells. We then assessed the effects of MSLN-NK cells on TNBC cells both in vitro (using the MDA-MB-231 cell line), in vivo (in a CDX mouse model), and ex vivo (using patient-specific primary cells and patient-specific organoids), in which MSLN surface expression was confirmed. Our CDX study results indicated that MSLN-NK cells effectively killed MDA-MB-231 (MD231) cells in vitro, reduced tumor growth in the CDX mouse model of TNBC, and lysed patient-specific primary cells and patient-specific organoids derived from the tumor samples of TNBC patients. Our data demonstrated that MSLN-NK cells had high efficacy on killing TNBC cells in in vitro, in vivo, and ex vivo. Therefore, MSLN-NK could be a promising treatment option for TNBC patients.
引用
收藏
页码:285 / 294
页数:10
相关论文
共 50 条
  • [21] TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
    Byrd, Tiara T.
    Fousek, Kristen
    Pignata, Antonella
    Szot, Christopher
    Samaha, Heba
    Seaman, Steven
    Dobrolecki, Lacey
    Salsman, Vita S.
    Oo, Htoo Zarni
    Bielamowicz, Kevin
    Landi, Daniel
    Rainusso, Nino
    Hicks, John
    Powell, Suzanne
    Baker, Matthew L.
    Wels, Winfried S.
    Koch, Joachim
    Sorensen, Poul H.
    Deneen, Benjamin
    Ellis, Matthew J.
    Lewis, Michael T.
    Hegde, Meenakshi
    Fletcher, Bradley S.
    St Croix, Brad
    Ahmed, Nabil
    CANCER RESEARCH, 2018, 78 (02) : 489 - 500
  • [22] From Interaction to Intervention: How Mesenchymal Stem Cells Affect and Target Triple-Negative Breast Cancer
    Wu, Yong
    Shum, Hang Chee Erin
    Wu, Ke
    Vadgama, Jaydutt
    BIOMEDICINES, 2023, 11 (04)
  • [23] Lysophosphatidic acid induced triple-negative breast cancer stem cells via TRPC3 channels
    Hirata, Naoya
    CANCER SCIENCE, 2023, 114 : 1135 - 1135
  • [24] Preclinical Evaluation of B7-H3-Targeted CAR-T Cells against Triple Negative Breast Cancer
    Jeon, Yeongha
    Ju, Anna
    Lee, Narim
    Lee, Sangeun
    Lee, Song-Jae
    Min, Sung-Won
    Park, Hye In
    Bae, Gong Deuk
    Lee, Ji Chul
    Song, Seong-Won
    MOLECULAR THERAPY, 2021, 29 (04) : 304 - 304
  • [25] EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo
    Xia, Lin
    Zheng, Zao-Zao
    Liu, Jun-Yi
    Chen, Yu-Jie
    Ding, Jian-Cheng
    Xia, Ning-Shao
    Luo, Wen-Xin
    Liu, Wen
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2020, 9 (05)
  • [26] Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells
    Yi, Yong Weon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [27] TEM8 specific CAR T cells induce regression of patient-derived xenograft and metastatic models of triple-negative breast cancer.
    Byrd, Tiara
    Fousek, Kristen
    Pignata, Antonella
    Szot, Christopher
    Samaha, Heba
    Dobrolecki, Lacey
    Oo, Htoo Zarni
    Sorensen, Poul
    Ellis, Matthew
    Lewis, Michael
    Hegde, Meenakshi
    Fletcher, Bradley
    St Croix, Brad
    Ahmed, Nabil
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 38 - 38
  • [28] Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer
    Erler, Piril
    Kurcon, Tomasz
    Cho, Hana
    Skinner, Jordan
    Dixon, Chantel
    Grudman, Steven
    Rozlan, Sandra
    Dessez, Emilie
    Mumford, Ben
    Jo, Sumin
    Boyne, Alex
    Juillerat, Alexandre
    Duchateau, Philippe
    Poirot, Laurent
    Aranda-Orgilles, Beatriz
    SCIENCE ADVANCES, 2024, 10 (35):
  • [29] Density Gradient Centrifugation Is an Effective Tool to Isolate Cancer Stem-like Cells from Hypoxic and Normoxia Triple-Negative Breast Cancer Models
    Sargiacomo, Camillo
    Klepinin, Aleksandr
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [30] RON Receptor-Targeted Antibody-Drug Conjugate Therapy Ablates Cancer Stem Cells and Induces Long-term Tumor Regressions in Preclinical Models of Triple-Negative Breast Cancer (TNBC)
    Suthe, Sreedhar Reddy
    Yao, Hang-Ping
    Wang, Ming-Hai
    FASEB JOURNAL, 2019, 33